http://orcid.org/0000-0003-2210-2174
References
- Kumar SK, Rajkumar SV. The multiple myelomas - current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018;15:409–421.
- Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J. 2015;5:e365.
- Greenberg AJ, Rajkumar SV, Therneau TM, et al. Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia. 2014;28:398–403.
- Shetty S, Siady M, Mallempati KC, et al. Utility of a column-free cell sorting system for separation of plasma cells in multiple myeloma FISH testing in clinical laboratories. Int J Hematol. 2012;95:274–281.
- Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955–2962.
- Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology–an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998;91:2501–2507.
- Moller HE, Preiss BS, Pedersen P, et al. Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort. Apmis. 2015;123:652–658.
- Oka SOK, Nohgawa M. Present study.
- Robillard N, Wuilleme S, Lode L, et al. CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target. Leukemia. 2005;19:2021–2022.
- Castella M, Fernandez de Larrea C, Martin-Antonio B. Immunotherapy: a novel era of promising treatments for multiple myeloma. Int J Mol Sci. 2018;19:3613. DOI:10.3390/ijms19113613